Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Activating Mutation”

133 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 133 results

Large-scale testing (Phase 3)Looking for participantsNCT05382728
What this trial is testing

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Who this might be right for
NSCLCEGFR Activating Mutation
TYK Medicines, Inc 680
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Testing effectiveness (Phase 2)Study completedNCT02616393
What this trial is testing

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Who this might be right for
Non-Small Cell Lung CancerLeptomeningeal MetastasesBrain Metastases
Kadmon Corporation, LLC 36
Testing effectiveness (Phase 2)WithdrawnNCT02355431
What this trial is testing

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Solid Tumors and Hematologic MalignancyNSCLC (Non-small Cell Lung Carcinoma)
Incyte Corporation
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)WithdrawnNCT01928160
What this trial is testing

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)Ended earlyNCT00988169
What this trial is testing

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Ended earlyNCT02095782
What this trial is testing

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 10
Testing effectiveness (Phase 2)UnknownNCT03341494
What this trial is testing

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Who this might be right for
NSCLC Stage IVChemotherapy Effect
Fujian Cancer Hospital 128
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Testing effectiveness (Phase 2)Study completedNCT05146219
What this trial is testing

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Who this might be right for
NSCLCEGFR Activating MutationBrain Metastases+1 more
TYK Medicines, Inc 29
Not applicableStudy completedNCT01167972
What this trial is testing

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 2,000
Not applicableNot Yet RecruitingNCT07287904
What this trial is testing

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationAdenocarcinoma Lung+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1,000
Testing effectiveness (Phase 2)Study completedNCT02264210
What this trial is testing

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Who this might be right for
Lung NeoplasmsSquamous Cell Lung CancerAdenocarcinoma of the Lung+4 more
Sun Yat-sen University 128
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149
What this trial is testing

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Who this might be right for
AumolertinibAnlotinibTP53+2 more
Tianjin Medical University Cancer Institute and Hospital 47
Testing effectiveness (Phase 2)Study completedNCT04764214
What this trial is testing

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Who this might be right for
NSCLC Stage IVEGFR Activating Mutation
Fudan University 61
Testing effectiveness (Phase 2)UnknownNCT03126799
What this trial is testing

Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
National Cancer Center, Korea 128
Testing effectiveness (Phase 2)UnknownNCT03486496
What this trial is testing

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Who this might be right for
Lung AdenocarcinomaEGFR Mutation
Fujian Cancer Hospital 50
Load More Results